

Takayuki Takahama

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2548545/publications.pdf>

Version: 2024-02-01

32
papers

921
citations

687363

13
h-index

501196

28
g-index

32
all docs

32
docs citations

32
times ranked

1764
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. <i>Annals of Oncology</i> , 2017, 28, 1532-1539.	1.2	239
2	B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity. <i>Clinical Cancer Research</i> , 2018, 24, 2653-2664.	7.0	109
3	Detection of the T790M mutation of <i>EGFR</i> in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR) <i>Tj ETQq1 1 0.784314 r08 /Over</i>	1.2	68
4	Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. <i>Annals of Oncology</i> , 2015, 26, 2477-2482.	1.2	68
5	Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib. <i>Annals of Oncology</i> , 2016, 27, 953-955.	1.2	67
6	The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 33602-33611.	1.8	53
7	Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2021, 26, e588-e596.	3.7	48
8	Clinical and immune profiling for cancer of unknown primary site. , 2019, 7, 251.		26
9	Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of <i>EGFR</i> or <i>HER2</i> . <i>Oncotarget</i> , 2018, 9, 21132-21140.	1.8	24
10	Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy. <i>Lung Cancer</i> , 2012, 77, 293-298.	2.0	23
11	New Era for Next-Generation Sequencing in Japan. <i>Cancers</i> , 2019, 11, 742.	3.7	22
12	Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. <i>Oncotarget</i> , 2016, 7, 84860-84871.	1.8	18
13	Plasma screening for the T790M mutation of <i>EGFR</i> and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study. <i>Cancer</i> , 2020, 126, 1940-1948.	4.1	18
14	Membranous glomerulonephritis associated with <i>Mycobacterium shimoidei</i> pulmonary infection. <i>American Journal of Case Reports</i> , 2013, 14, 543-547.	0.8	14
15	A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing. <i>Scientific Reports</i> , 2019, 9, 11340.	3.3	12
16	Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors. <i>Scientific Reports</i> , 2019, 9, 19501.	3.3	12
17	Predicting osimertinib treatment outcomes through <i>EGFR</i> mutant fraction monitoring in the circulating tumor DNA of <i>EGFR</i> T790M-positive patients with non-small cell lung cancer (WJOG8815L). <i>Molecular Oncology</i> , 2021, 15, 126-137.	4.6	12
18	Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease. <i>Investigational New Drugs</i> , 2016, 34, 394-396.	2.6	11

#	ARTICLE	IF	CITATIONS
19	CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M ⁺ positive lung cancer after osimertinib. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1628-1639.	2.2	11
20	Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial. <i>Medical Oncology</i> , 2021, 38, 128.	2.5	11
21	Phase II Trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer. <i>Oncologist</i> , 2019, 24, 163.	3.7	10
22	Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer. <i>In Vivo</i> , 2020, 34, 1921-1929.	1.3	9
23	A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS. <i>Clinical Breast Cancer</i> , 2019, 19, e589-e592.	2.4	8
24	Paraneoplastic Focal Segmental Glomerulosclerosis in a Patient with Lung Adenocarcinoma. <i>Internal Medicine</i> , 2013, 52, 1953-1956.	0.7	6
25	Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs. <i>Lung Cancer</i> , 2020, 139, 28-34.	2.0	5
26	Anaplastic Lymphoma Kinase Gene Analysis as a Useful Tool for Identifying Primary Unknown Metastatic Lung Adenocarcinoma. <i>Internal Medicine</i> , 2014, 53, 2711-2715.	0.7	4
27	A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer. <i>BMC Research Notes</i> , 2015, 8, 100.	1.4	4
28	Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis. <i>Journal of Thoracic Oncology</i> , 2019, 14, e50-e52.	1.1	4
29	Durable response to EGFR tyrosine kinase inhibitors in a patient with non-small cell lung cancer harboring an EGFR kinase domain duplication. <i>Thoracic Cancer</i> , 2021, 12, 2283-2287.	1.9	3
30	Implementation of clinical sequencing for molecular profiling in patients with advanced cancer. <i>Cancer Biomarkers</i> , 2021, 31, 119-126.	1.7	1
31	Phase II study of osimertinib in patients with plasma EGFR T790M positive advanced lung cancer (WJOG8815L/LPS). <i>Annals of Oncology</i> , 2018, 29, vii50.	1.2	0
32	Potential research and clinical utility of liquid biopsy with CAPP seq. <i>Annals of Oncology</i> , 2018, 29, vii27.	1.2	0